Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects  by Napolitano, Antonella et al.
Contents lists available at ScienceDirect
Journal of Clinical & Translational Endocrinology
journal homepage: www.elsevier .com/locate/ jcte
Journal of Clinical & Translational Endocrinology 1 (2014) e3ee8Research PaperExploring glycosuria as a mechanism for weight and fat mass
reduction. A pilot study with remogliﬂozin etabonate and sergliﬂozin
etabonate in healthy obese subjects
Antonella Napolitano a,*, Sam Miller a, Peter R. Murgatroyd c, Elizabeth Hussey b,
Robert L. Dobbins b, Edward T. Bullmore a, Derek J.R. Nunez b
a Clinical Unit in Cambridge, GlaxoSmithKline, Addenbrookes Hospital, Cambridge, UK
bMetabolic Pathways and Cardiovascular Unit, GlaxoSmithKline, NC, USA
cWellcome Trust Clinical Research Facility, Cambridge University Hospital NHS Trust, UKa r t i c l e i n f o
Article history:
Received 16 October 2013
Received in revised form
26 November 2013
Accepted 5 December 2013





Glycosuria* Corresponding author. Experimental Medicine
Therapy Unit, GlaxoSmithKline Medicines, Stevenage,
7906323501.
E-mail address: antonella.2.napolitano@gsk.com (A
2214-6237 2014 Elsevier Inc.
http://dx.doi.org/10.1016/j.jcte.2013.12.001
Open access under CC BY-a b s t r a c t
Inhibitors of sodium-dependent glucose co-transporter 2 (SGLT2) increase glucose excretion in the urine
and improve blood glucose in Type 2 diabetes mellitus. Glycosuria provides an energy and osmotic drain
that could alter body composition. We therefore conducted a pilot study comparing the effects on body
composition of two SGLT2 inhibitors, remogliﬂozin etabonate (RE) 250 mg TID (n ¼ 9) and sergliﬂozin
etabonate (SE) (1000 mg TID) (n ¼ 9), with placebo (n ¼ 12) in obese non-diabetic subjects. Both drugs
were well tolerated during 8 weeks of dosing, and the most common adverse event was headache. No
urinary tract infections were observed, but there was one case of vaginal candidiasis in the RE group. As
expected, RE and SE increased urine glucose excretion, with no change in the placebo group. All the
subjects lost weight over 8 weeks, irrespective of treatment assignment. There was a reduction in TBW
measured by D2O dilution in the RE group that was signiﬁcantly greater than placebo (1.4 kg, p ¼ 0.029).
This was corroborated by calculation of fat-free mass using a quantitative magnetic resonance technique.
All but one subject had a measurable decrease in fat mass. There was signiﬁcant between-subject
variability of weight and fat loss, and no statistically signiﬁcant differences were observed between
groups. Despite a lack of a difference in weight and fat mass loss, the leptin/adiponectin ratio, a measure
of insulin resistance, was signiﬁcantly decreased in the RE group when compared to placebo and SE,
suggesting that this SGTL-2 inhibitor may improve metabolic health independent of a change in fat mass.
 2014 Elsevier Inc.Open access under CC BY-NC-ND license. Introduction
The incidence and prevalence of Type 2 diabetes (T2DM) are
increasing as the result of a worldwide epidemic of obesity [1].
Medical management of patients with T2DM includes diet, exer-
cise and weight reduction, together with oral anti-diabetic med-
ications or insulin therapy, when appropriate [2]. Frequently, the
treatment of T2DM now requires multiple agents acting via
complementary mechanisms in an attempt to achieve tighter
glycemic targets. Consequently, new agents with unique mecha-
nisms of action and limited side effect proﬁles are needed when
these targets cannot be reached [3].Unit, Immuno-inﬂammation
Hertfordshire, UK. Tel.: þ44
. Napolitano).
NC-ND license. Inhibitors of sodium-dependent glucose co-transporter 2
(SGLT2) reduce circulating glucose concentrations via a renal
mechanism distinct from other current anti-diabetic agents [4].
SGLT2 is primarily expressed on the luminal side of the renal
proximal tubule. It has high solute translocation capacity and
low substrate afﬁnity, and serves as the primary, but not exclu-
sive, pathway for renal glucose reabsorption. Sergliﬂozin eta-
bonate (SE) and remogliﬂozin etabonate (RE) are orally-active
prodrugs of sergliﬂozin and remogliﬂozin, respectively. Sergli-
ﬂozin is an SGLT2 inhibitor that increases urinary glucose
excretion in a dose-dependent manner in rodents and dogs, and
lowers plasma glucose levels following oral glucose challenge in
diabetic rats [5]. Remogliﬂozin works similarly in mice and rats
and exhibits antidiabetic efﬁcacy in animal models and humans
[6e8]. These two SGTL2 inhibitors have different effects on
glucose excretion in humans. The maximal glycosuria observed
with RE is greater than the maximal glycosuria achieved with
SE [7,8].
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lower body weight in subjects with T2DM [8]. Administration of RE
for 12 weeks to T2DM subjects resulted in a reduction of HbA1c of
up to 1.07% versus placebo treatment, and a reduction in body
weight of up to 3.51 kg (unpublished data). In another 12-week
study conducted with T2DM subjects, dapagliﬂozin, a different
SGLT2 inhibitor, improved HbA1c and produced weight changes
of 2.5 to 3.4 kg compared to 1.2 kg for placebo [9]. No detailed
body composition analyses were included in these studies to
investigate the mechanism of the weight loss.
The renal glycosuria produced by SGLT2 inhibitors could alter
body composition through loss of calories in the urine and by os-
motic diuresis. In addition, initial weight changes during negative
energy balance could be the result of diuresis caused by glycogen
mobilization from the liver. If the sustained weight changes are the
result of reduced adipose tissue stores caused by energy excretion
as glucose, then this may explain, in part, the metabolic improve-
ment seen with SGLT2 inhibitors.
The primary objective of this pilot study was to investigate the
effect of RE and SE, administered for 8 weeks, on glucose excretion
and body composition changes measured by quantitative magnetic
resonance (QMR) [10], and by the 4-compartment (4C) body
composition model [11]. In addition, we measured the changes in
total body water (TBW) to determine the contribution of ﬂuid loss
caused by osmotic diuresis to the overall change in weight seen
with these SGLT2 inhibitors.
Materials and methods
The study was conducted at the Addenbrookes Centre for
Clinical Investigation (ACCI), Addenbrooke’s Hospital, Cambridge,
UK, in the GlaxoSmithKline Clinical Unit in Cambridge (CUC) and
the Wellcome Trust Clinical Research Facility (WTCRF). The study
was performed in accordance with Good Clinical Practice guide-
lines and the 1996 version of the Declaration of Helsinki and it
was conducted between September 2006 and July 2007. The
experimental protocols were approved by the protocol review
panel at GlaxoSmithKline, the Cambridge Local Research Ethics
Committee (06/Q0108/254) (EUDRACT 2006-003864-71), the
Addenbrooke’s Hospital R&D ofﬁce, and by the WTCRF Scientiﬁc
Advisory Board. All patients provided written informed consent
prior to participation.
Thirty healthy subjects were recruited by direct advertisement.
The sample size of this pilot study was based on feasibility.
Enrollment criteria included body mass index (BMI) between 30
and 40 kg/m2 and age between 18 and 55 years. Subjects with
T2DM were excluded. The use of recreational drugs, alcohol,
caffeine and strenuous exercise was forbidden. A qualiﬁed dietician
advised subjects on a hypocaloric diet targeting a daily energy
deﬁcit of 2090 kJ [12] relative to the estimated daily caloric
requirement of each subject, assuming a physical activity level of
1.3. After a 2 week run-in on diet alone, baseline 24 h urine glucose
excretion, weight and fat mass were measured using QMR and 4C
methods. Subjects were then assigned at random in a 3:3:2:2 ratio
to SE 1000mg three times daily [TID] (n¼ 9), RE 250mg TID (n¼ 9),
SE-placebo TID (n ¼ 6), or RE-placebo TID (n ¼ 6). Subjects were
managed as outpatients and returned to the clinical unit every two
weeks for eight weeks to receive counseling and to review safety
endpoints. After eight weeks of dosing, they again underwent
measurement of 24 h urine glucose excretion, weight and fat mass.
Intermediate measurements of some pharmacodynamic endpoints
were made at weeks 2, 4 and/or 6 and at a follow-up visit at week
12. Plasma sampling occurred at Week 6 to determine steady-state
pharmacokinetics (PK) of RE, remogliﬂozin and GSK279782 (the
main remogliﬂozin metabolite), and SE.Fasting blood samples were collected at the beginning of the
study and at clinic visits for leptin, adiponectin, IGF-1, VCAM-1.
Body composition measurements
Quantitative magnetic resonance
The characteristics of the QMR (Echo MRI-AH, Echo Medical
Systems, Houston, TX, USA) have been described previously [10,13].
This methodology provides a rapid, non-invasive and highly precise
measurement of human body fat using the nuclear magnetic
resonance properties of protons to separate signals originating from
fat and non-fat tissues. All QMR measurements were made in
triplicate.
4-compartment model
Fat mass was also estimated using the following 4C equation
[14]:
Fat mass ¼ ½2:747  BV  ½0:71  TBW þ ½1:46  BMC
 ½2:05  BM
Where BV is body volume in liters and all other variables are in
kilograms (TBW ¼ total body water, BMC ¼ bone mineral content,
BM ¼ body mass). BV was derived from a BOD POD (Life Mea-
surement Inc, Concord, CA, USA) using estimates of % body fat and
BM as follows [4]:
BV ¼ ð% fat þ 450Þ  BM=495:
TBW was measured by D2O dilution using a protocol designed
in collaboration with the MRC Human Nutrition Research Group,
Cambridge, UK, where the deuterium analysis was performed
[15]. Subjects were fasted from 22:00 and at 06:00 the next
morning they were awakened and asked to provide samples of
saliva and voided urine for D2O analysis. D2O-enriched water
(100 g of 7% by mass D2O in H2O) was then consumed, and
further saliva samples were taken at 4, 5 and 6 h post dose. Up to
the 6 h sample, the volume of all urine passed was recorded and
assayed for D2O content to correct for label lost from the body
water pool.
Total body BMC was estimated fromwhole-body dual-energy x-
ray absorptiometry (DXA) scans (GE Lunar Prodigy, software
version 8.1 GE Lunar, Madison, WI USA).
Urinary glucose excretion
Urine was collected over 24-h intervals during clinic visits
scheduled at Week 0, 2, 4, and 8, and urine samples were collected
over 6-hour at Week 6 for measurement of drug concentrations.
Aliquots taken from these urine collections were analyzed for urine
glucose (molar units) and volume (milliliters). From these 2 mea-
sures, urine glucose excretion (mmol/24 h) and energy loss (kJ and
kcal) were estimated. Urine energy loss was calculated from urine
glucose excretion as follows:
Urine glucose in molar units was converted to grams by multi-
plying by 180.2. This value was then converted into energy in joules
by multiplying by 15.76 and to kilocalories by dividing by 4.186.
Urine glucose excretion on between the clinic visits was estimated
using linear interpolation.
Hormone and peptide assays
The NIHR Cambridge Biomedical Research Centre, Core
Biochemical Assay Laboratory analyzed the leptin and adiponectin
using a two-site microtiter plate-based DELFIA assay [16], as well as
IGF-1 (Siemens Healthcare Diagnostics) and VCAM-1 (Human
VCAM-1 assay; R&D Systems Europe, Abingdon, UK).
Table 1
Population characteristics
All subjects (N ¼ 30)
Sex Male, n (%) 22 (73%)
Female, n (%) 8 (27%)
Ethnicity White/Caucasian/
European heritage, n (%)
29 (97%)
Other (not speciﬁed), n (%) 1 (3%)
Age, years Mean (SD) [range] 42 (13.0) [18e63]
Weight, kg Mean (SD) [range] 101 (14.6) [76.7e138.0]
BMI, kg/m2 Mean (SD) [range] 33 (2.4) [30.5e40.1]
Fasting plasma
glucose, mMol/L
Mean (SD) [range] 5.7 (0.59) [4.8e7.3]
Fat (QMR), kg Mean (SD) 34 (7.3)
Fat (4C), kg Mean (SD) 39 (7.0)
Fat free mass, kg Mean (SD) 67 (13.7)
Total body water
(D2O), kg
Mean (SD) 47 (8.6)
Leptin/adiponectin
ratio
Geometric mean (%CV) 0.0047 (150%)
Figure 1. Urine glucose excretion over time. Urine samples were collected over 24 h at
baseline, week 2, 4 and 8 study visits. Means and 95% conﬁdence intervals are reported.
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Blood and urine samples were collected for the determination of
RE (prodrug), remogliﬂozin (active entity), GSK279782 (the main
remogliﬂozin metabolite), SE (prodrug), sergliﬂozin (active entity)
in plasma. Samples were analyzed by Worldwide Bioanalysis,
GlaxoSmithKline Pharmaceuticals (Research Triangle Park, NC,
USA) using protein precipitation, followed by high performance
liquid chromatography tandem mass spectrometric (HPLC/MS/MS)
detection [8].
Statistical analysis
Subjects from the two placebo groups were pooled into a single
group for the analysis and presentation of results. The primary
endpoints of the trial were change from baseline in fat mass mea-
surements measured by QMR and the 4C model, body weight and
urine glucose excretion. Endpoints were analyzed by separate
mixed effect, repeated measures analysis of variance models. Terms
were included for treatment group, visit, treatment-by-visit inter-
action, the baseline measurement, the baseline measurement-by-
visit interaction and sex. Subject was ﬁtted as a random variable.
On the basis of the Akaike’s Information Criterion, no speciﬁc
structure was imposed on the correlations between visits. Point
estimates and 95% conﬁdence intervals were constructed using the
appropriate variance term for the differences between visits within
groups (e.g., estimating change from baseline for sergliﬂozin eta-
bonate) for each treatment and for differences between treatments
(e.g., comparing the baseline-to-Week 8 changes in the sergliﬂozin
etabonate group with placebo). A similar model was ﬁtted to
analyze change in body weight and urine glucose excretion. Urine
glucose excretion data were log-transformed for analysis because
there was evidence of increasing variance with increases in urine
glucose excretion. A 5% signiﬁcance level was used for all analyses.
No adjustments for multiplicity were made. Analysis was carried
out in SAS Version 9 for Windows.
Exploratory analyses were performed to investigate the re-
lationships between fat mass, TBW and plasma leptin and
adiponectin.
Results
Thirty subjects who met the eligibility criteria were random-
ized into the study between October 2006 and May 2007. Baseline
characteristics of the randomized subjects are given in Table 1. Of
these, 27 completed the study. One subject in each treatmentgroup withdrew consent prior to week 8 because they were un-
able to attend all protocol-required clinic visits. No serious adverse
events were reported for the randomized subjects, and the most
frequently reported adverse event was mild headache (44% for RE,
33% for SE and 50% for placebo). No urinary tract infections were
observed during the study. There was one case of vaginal candi-
diasis occurring at the end of the 8-week treatment regimen with
RE. No signiﬁcant changes were observed on the safety laboratory
parameters.
As previously demonstrated [5,8], both RE and SE increased
urinary glucose excretion (Figure 1). The within-group increases in
urine glucose excretion from baseline to Week 8 for subjects in the
SE and RE groups were 247 mmol/24 h (CV: 15%) and 400 mmol/
24 h (CV: 15%), respectively (both p < 0.0001). Furthermore, the
change from baseline toWeek 8 urine glucose excretionwas greater
with RE than with SE (p ¼ 0.020). As expected, no urine glucose
excretion was observed in the placebo group.
Statistically signiﬁcant decreases in body mass from baseline
values to Week 8 were observed for RE (7.6 kg) and SE (6.1 kg),
but these decreases were not signiﬁcantly greater than the weight
loss observed in the placebo group (5.1 kg) (Table 2). For all three
treatment groups, weight loss was associated with changes of
anthropometric parameters, including BMI, waist circumference
and hip circumference. Consistent with the results for body weight,
all treatment groups exhibited a statistically signiﬁcant decrease in
fat mass as measured using both QMR and the 4C model. Even
though there was increased urine glucose and energy excretion
produced by the SGLT2 inhibitors, there were no measurable dif-
ferences of fat mass and weight relative to the placebo group
(Table 2 and Figure 2A and B).
The change in fat mass by QMR was similar in all three groups
(4.1 kg, 3.4 kg and 3.1 kg, for RE, SE and placebo, respectively).
The estimated mean amounts of total energy loss over 8 weeks
resulting from urine glucose excretion were 55.8 MJ (equivalent to
1.4 kg of fat), 35.4 MJ (equivalent to 0.9 kg of fat) and 0.061 MJ for
the RE, SE and placebo groups, respectively. These equate to average
daily values of 1000 kJ/day (240 kcal/day), 630 kJ/day (150 kcal/day)
and 1.1k J/day (0.3 kcal/day) energy loss via urine for the RE, SE and
placebo groups, respectively.
Figure 3 displays a comparison of the estimated total urine
glucose energy loss (MJ) for each subject versus their respective fat
loss converted into its energy equivalent. Across the treatment
groups there was a trend for subjects who had greater energy loss
through glycosuria to have a greater loss of fat mass, but this rela-
tionship was not statistically signiﬁcant (p > 0.05).
Table 2
Summary of changes from baseline to week 8
Endpoint Placebo Remogliﬂozin etabonate Sergliﬂozin etabonate Difference from placebo
Remogliﬂozin etabonate Sergliﬂozin etabonateN ¼ 11 N ¼ 8 N ¼ 8
Weight (kg) 5.1 (7.1, 3.2) 7.6 (10.0, 5.2) 6.1 (8.4, 3.8) 2.5 (5.6, þ0.6) 1.0 (3.9, þ2.0)
p < 0.001 p < 0.001 p < 0.001 p ¼ 0.105 p ¼ 0.511
Fat mass (QMR) (kg) 3.4 (4.9, 2.0) 4.1 (5.9, 2.3) 3.1 (4.8, 1.4) 0.7 (3.0, þ1.7) þ0.3 (1.9, þ2.5)
p < 0.001 p < 0.001 p < 0.001 p ¼ 0.565 p ¼ 0.786
Fat free mass (QMR) (kg) 1.5 (2.3, 0.7) 2.7 (3.7, 1.8) 2.2 (3.2, 1.3) 1.3 (2.5, 0.0) 0.8 (2.0, þ0.5)
p < 0.001 p < 0.001 p < 0.001 p ¼ 0.048 p ¼ 0.209
Fat mass (4C) (kg) 4.6 (6.5, 2.7) 4.8 (7.2, 2.5) 3.8 (6.1, 1.6) 0.2 (3.1, þ2.8) þ0.8 (2.0, þ3.7)
p < 0.001 p < 0.001 p ¼ 0.002 p ¼ 0.906 p ¼ 0.564
Total body water (D2O) (kg) 0.3 (1.1, þ0.5) 1.7 (2.6, 0.8) 1.1 (2.0, 0.1) 1.4 (2.6, 0.2) 0.8 (2.0, þ0.5)
p ¼ 0.434 p ¼ 0.001 p ¼ 0.025 p ¼ 0.029 p ¼ 0.206
Leptin/adiponectin ratio (%) 7% (37%, þ36%) 46% (62%, 22%) 3% (31%, þ36%) 41% (65%, 2%) þ4% (37%, þ72%)
p ¼ 0.685 p ¼ 0.006 p ¼ 0.822 p ¼ 0.033 p ¼ 0.704
BMI (kg/m2) 1.7 (2.3, 1.0) 2.4 (3.1, 1.6) 2.0 (2.7, 1.3)
Hip (cm) 3.1 (5.1, 1.2) 3.0 (7.4, þ1.4) 1.9 (6.2, þ2.5)
Waist (cm) 2.8 (6.3, þ0.7) 4.2 (9.5, þ1.2) 4.6 (6.9, 2.2)
Weight lost as fat, % (QMR) 63% (44%, 83%) 57% (41%, 73%) 65% (40%, 89%)
Values are mean (except for leptin/adiponectin ratio which is geometric mean), 95% conﬁdence interval, and p-values for key endpoints.
Fat free mass calculated as weight  fat mass (QMR).
Weight lost as fat calculated as 100  fat loss (QMR).
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balance resulting from the dietary restriction (500 kcal/day;
2090 kJ/day on each of 56 days ¼ 117 MJ) plus any given urine
glucose excretion (e.g., a subject with estimated urine glucoseFigure 2. (A) Changes in fat mass over time Fat mass was measured in triplicate by
QMR at baseline, week 2, week 4 and week 8 study visits. Means and 95% conﬁdence
intervals are shown. (B) Changes in weight over time body weight was measured at
baseline, week 2, week 4 and week 8 study visits. Means and 95% conﬁdence intervals
are shown.excretion of 30 MJ has a projected total energy loss of 147 MJ). The
theoretical projections can be seen to lie centrally within the spread
of the observed data points.
The measurements of TBW before and after 8 weeks of dosing
are reported in Table 2. Compared to baseline, there were statisti-
cally signiﬁcant reductions of TBWof 1.7 kg and 1.1 kg for RE and SE,
respectively, but there was no change in the placebo group.
Compared to placebo, there was a statistically signiﬁcant reduction
of TBW with RE, but not SE.
No treatment-related changes in mean adiponectin and IGF-1
concentrations were observed. Baseline leptin concentrations
were related to baseline fat mass measurements, and leptin con-
centrations decreased over the course of the study. The changes in
leptin concentration were consistent with fat mass changes in all
the treatment groups. There was a trend for mean VCAM-1 levels to
increase over the course of the study for all treatment regimens
(data not shown).
The leptin/adiponectin ratio (LAR) decreased by 46% from
baseline to Week 8 in the RE group, and this was signiﬁcantly more
than was seen in the placebo (7%) or SE (3%) groups (Table 2).Figure 3. Relationship between urine glucose excretion and loss of fat mass over 8
weeks. Individual subject values of glycosuria and QMR fat mass changes have been
converted to energy equivalents (MJ).
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(Figure 4).
Pharmacokinetic analyses at Week 6 conﬁrmed that the steady-
state exposures of RE and SE in this obese population (data not
shown) were comparable to those previously reported in diabetic
patients and normal lean volunteers [8].
Discussion
At the time this study was designed therewas not information on
the effects of SGLT2 inhibitors in obese humans. As a result, we
investigated the actions of two SGTL2 inhibitorswith different effects
onglucoseexcretion inobese, non-diabetic subjects, andattempted to
relate the energy lost through glycosuria to changes in weight and
body composition as assessed by the state-of-the-art methods,
QMR and the 4C model. Previously, we had demonstrated that QMRFigure 4. Correlation of leptin/adiponectin, leptin and fat mass. Correlation of change
of leptin /adiponectin ratio (LAR) versus change of fat mass (week 8eweek 0) (A) and of
change of leptin versus change of fat mass (week 8eweek 0) (B).was the most precise way of detecting changes fat mass [10,13]. We
also used D2O dilution to measure TBW to quantify the ﬂuid shifts
producedby SGLT2 inhibition in these non-diabetic subjects. Afterwe
started our study, two SGLT2 inhibitors have been shown to cause
weight loss in T2DM subjects. Administration of RE for 12 weeks to
T2DM subjects resulted in reductions in body weight of up to 3.5 kg
compared toplacebo, in addition to loweringHbA1c, but nodatawere
collected on body composition changes (unpublished data). Dapa-
gliﬂozin administered for 24 weeks to T2DM patients reduced total
body weight and fat mass [9].
In the present study, we have extended the initial observations of
the actions of SGLT2 inhibitors to obese non-diabetic subjects. As
anticipated, there was a statistically signiﬁcant treatment-related
effect of RE and SE on urine glucose excretion, with RE producing
greater urine glucose excretion than SE, as expected from the differ-
ences in drug exposure and potency of the two inhibitors. There was
no change in glucose excretion in the placebo groups. These treat-
ment- andvisit-relatedchanges inurineglucoseexcretion translate to
mean differences in urine energy loss of 55.8MJ, 35.4MJ and 0.06MJ
for the RE, SE and placebo groups, respectively. In contrast, urine
volumemeasureswere relatively consistent among treatment groups
and stable over the treatment periods (data not shown).
All the obese subjects lost weight over 8 weeks, irrespective of
treatment assignment, and all but one subject had a measurable
decrease in fat mass. Notably, the degree of weight and fat loss
varied considerably between individuals (e.g., weight loss on pla-
cebo ranged from1.3 to 11.9 kg over the eight weeks period). In light
of this large between-subject variation and the small size of the
study population, it is not surprising that there were no statistically
signiﬁcant differences between active treatment and placebo
groups with regard to weight or fat loss. The weight changes in
these subjects would be expected to result from the difference
between energy intake and energy expenditure or energy loss as
glycosuria. In our study, the protocol required a behavioral modi-
ﬁcation that should have resulted in a negative daily energy intake
of 2090 kJ (500 calories) for all subjects over the duration of the
trial. In addition, the estimated mean total daily energy loss as
glycosuria was approximately 1000 kJ/day (240 kcal/day), 630 kJ/
day (150 kcal/day) and 1.1 kJ/day (0.3 kcal/day) for the RE, SE and
placebo groups, respectively. Furthermore, the RE group at week 8
showed a reduction in TBWmeasured by D2O that was signiﬁcantly
greater than placebo (1.4 kg, p ¼ 0.029). This was corroborated by
calculation of fat-free mass (weight  fat mass measured by QMR)
which remained unchanged in the placebo group at 8 weeks, but
was signiﬁcantly decreased in the SGTL-2 inhibitor-treated groups.
We found that the changes in fat-free mass correlated with TBW
changes (r ¼ 0.55), but the former seemed to decrease more in the
SGLT2 treated groups than TBW changes. We have no data on
changes on glycogen storage, but these would occur early and
would be expected to have little impact on absolute hydration
status at the end of 8 weeks of treatment.
The size of the study population was limited, but taken together
these data suggest two possibilities for the lack of differentiation of
theweight changes seenwith the SGLT2-treated and placebo-treated
subjects: (i) placebo-treated subjects were more compliant with the
behavioral modiﬁcations required by the protocol, creating a more
variable, and in some cases greater, negative energy balance, and/or
(ii) the SGLT2 inhibitors stimulated food intake as a compensation for
the energy loss as glycosuria, and this was large enough to over-
shadow the weight loss from urinary calorie loss and osmotic
diuresis. The food intake and energy expenditure information
collected during the study by the dieticians was not sufﬁciently
detailed to investigate this possibility. However, it has been reported
that SGLT2 inhibitionmay increase food intake in an animalmodel of
obesity [17].
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insulin resistance in non-diabetic individuals [18], and it was sur-
prising that there was a signiﬁcant decrease between baseline at
the end of the intervention in the RE group when compared to
placebo and SE, suggesting that this SGTL-2 inhibitor improved
metabolic health independent of a signiﬁcant change in fat mass.
The difference between the RE and SE groups may indicate that the
degree of glycosuria may be important in activating a novel
mechanism leading to the reduction of the leptin-adiponectin ratio.
In conclusion, we have demonstrated that administration of
SGLT2 inhibitors to obese non-diabetic subjects increases energy
loss via urine glucose excretion. We observed statistically signiﬁ-
cant and comparable reductions of weight and fat mass in the
SGLT2 and placebo groups which may indicate that SGLT2 inhibi-
tion drives some compensatory increase in energy intake. In
addition, RE produced a statistically signiﬁcant reduction of fat-
free mass and TBW. The reduction of the leptin-adiponectin ratio
suggests that RE, but not SE, treatment is capable of improving the
metabolic status of on non-diabetic obese subjects. As this was a
small pilot study, a long-termweight loss trialwould be required to
conﬁrm our observations. Ideally, the trial would thoroughly
assess energy balance and monitor food intake and energy
expenditure, to allow deconvolution of the factors contributing to
the variability between individuals in response to an SGLT2 in-
hibitor. The favorable body composition and metabolic changes in
non-diabetic obese subject should be investigated further when
SGLT2 inhibitors are used asmonotherapy orwhen combinedwith
other weight loss treatments.
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